/
DERM
$6.79+$0.17 (+2.57%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$182.3M
28M shares
52-week range
$4.31 – $9.56
47% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.65%
Moderate
Price (6 mo)
Loading chart…
Change$-2.71
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $42.3M | $34.9M | $44.5M | $63.1M | $73.7M | $79.2M | $56.1M | $61.9M |
| Cost of revenue | $1.2M | $10.5M | $14.6M | $32.1M | $30.8M | $26.7M | $20.9M | $25.2M |
| Gross profit | $41.2M | $24.4M | $29.9M | $31.1M | $42.9M | $52.5M | $35.3M | $36.7M |
| Gross margin | 97.2% | 69.8% | 67.2% | 49.2% | 58.2% | 66.3% | 62.8% | 59.3% |
| R&D | $80.5M | $0 | $0 | $16.6M | $10.9M | $7.5M | $9.9M | $480.0K |
| Operating income | −$214.0M | $5.3M | $7.9M | −$34.9M | −$27.5M | −$2.1M | −$13.7M | −$8.2M |
| EBITDA | −$205.5M | $6.4M | $9.3M | −$32.8M | −$23.2M | $1.9M | −$8.4M | −$3.3M |
| Net income | −$221.5M | $3.6M | $5.3M | −$44.0M | −$29.6M | −$3.9M | −$14.7M | −$11.4M |
| Net margin | -523.3% | 10.4% | 11.9% | -69.7% | -40.2% | -4.9% | -26.1% | -18.5% |
| EPS (diluted) | -5.27 | 0.22 | 0.32 | -2.54 | -1.69 | -0.21 | -0.72 | -0.47 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $83M | $0.07 | $-0.02–$0.14 | 3 |
| 2027 | $138M | $1.04 | $0.81–$1.26 | 3 |
| 2028 | $198M | $2.25 | $1.73–$2.76 | 2 |
| 2029 | $225M | $1.42 | $1.31–$1.53 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Journey Medical Corporation Common Stock
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
www.jmcderm.com- Employees
- 58
- IPO / List date
- Nov 12, 2021
- HQ
- SCOTTSDALE, AZ
Held by traders on TradeandTell
No one on the platform currently holds DERM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 242,500 | $1.1M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded DERM yet.
